Neuvotion received FDA 510(k) clearance for its first product, the NeuStim wearable device. The company designed NeuStim to electrically stimulate muscles dynamically and with high precision. It supports hand movement recovery after stroke or spinal cord injury (SCI). The system enables clinicians to quickly scan and pinpoint stimulation targets through an innovative touch-screen interface.
Neuvotion said its system enables quick setup and saving for each user through a graphical user interface on a lightweight mobile device. The Stamford, Connecticut-based company plans to launch NeuStim in the U.S. in the coming year.
Related: Ibex Medical Analytics receives first FDA 510(k) clearance for Ibex Prostate Detect
The company develops neuromodulation products for use in the neurorehabilitation, brain-computer interface (BCI), and physical therapy markets. The company aims to facilitate and restore movement and sensation in patients experiencing impairment from stroke, spinal cord injury (SCI) and other conditions.
Neuvotion’s technologies combine high-precision neurostimulation and AI to accelerate rehab. The company says they make physical and occupational therapy more effective and efficient. It aims to help improve patient outcomes, independence and overall quality of life, Chad Bouton, founder and CEO, says.
In December, the company expanded its partnership with Intelligent Product Solutions (IPS) to help bring its neurostimulation product to market.
“At Neuvotion we are developing highly innovative technologies built on two decades of scientific research yielding effective and easy-to-use products,” said Bouton. “We are extremely excited about NeuStim, our first product, which we believe will be a game-changer in the neuromodulation, brain-computer interface, and neurorehabilitation markets.”
